Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NNZ-2591 by Acadia Pharmaceuticals for Rett Syndrome: Likelihood of Approval
NNZ-2591 is under clinical development by Acadia Pharmaceuticals and currently in Phase I for Rett Syndrome. According to GlobalData, Phase...
ACP-204 by Acadia Pharmaceuticals for Psychosis: Likelihood of Approval
ACP-204 is under clinical development by Acadia Pharmaceuticals and currently in Phase III for Psychosis. According to GlobalData, Phase III...
ACP-204 by Acadia Pharmaceuticals for Alzheimer's Disease: Likelihood of Approval
ACP-204 is under clinical development by Acadia Pharmaceuticals and currently in Phase III for Alzheimer's Disease. According to GlobalData, Phase...
Pimavanserin tartrate by Acadia Pharmaceuticals for Autism Spectrum Disorder (ASD): Likelihood of Approval
Pimavanserin tartrate is under clinical development by Acadia Pharmaceuticals and currently in Phase III for Autism Spectrum Disorder (ASD). According...